Rescue, amplification, purification, and PEGylation of replication defective first-generation adenoviral vectors.

Michael A. Barry, Eric A. Weaver, Sean E. Hofherr

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Adenoviral gene therapy vectors have been widely studied and used. Their extremely high transduction efficiency and gene delivery in vivo make them attractive for cancer gene therapy approaches. While they are robust, they are also very immunogenic. One approach to mitigate the immunogenicity of adenoviruses and to evade neutralizing antibodies is to coat the virus with the hydrophilic polymer polyethylene glycol (PEG) (1). This chapter details the steps involved when going from recombinant adenoviral vector plasmid all the way to validated PEGylated adenovirus product.

Original languageEnglish (US)
Pages (from-to)227-239
Number of pages13
JournalMethods in molecular biology (Clifton, N.J.)
Volume651
DOIs
StatePublished - Nov 12 2010

Fingerprint

Adenoviridae
Genetic Therapy
Neoplasm Genes
Neutralizing Antibodies
Polymers
Plasmids
Viruses
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Rescue, amplification, purification, and PEGylation of replication defective first-generation adenoviral vectors. / Barry, Michael A.; Weaver, Eric A.; Hofherr, Sean E.

In: Methods in molecular biology (Clifton, N.J.), Vol. 651, 12.11.2010, p. 227-239.

Research output: Contribution to journalArticle

@article{1df6f3c1568b47cd99c6aeb6ce6bfcb3,
title = "Rescue, amplification, purification, and PEGylation of replication defective first-generation adenoviral vectors.",
abstract = "Adenoviral gene therapy vectors have been widely studied and used. Their extremely high transduction efficiency and gene delivery in vivo make them attractive for cancer gene therapy approaches. While they are robust, they are also very immunogenic. One approach to mitigate the immunogenicity of adenoviruses and to evade neutralizing antibodies is to coat the virus with the hydrophilic polymer polyethylene glycol (PEG) (1). This chapter details the steps involved when going from recombinant adenoviral vector plasmid all the way to validated PEGylated adenovirus product.",
author = "Barry, {Michael A.} and Weaver, {Eric A.} and Hofherr, {Sean E.}",
year = "2010",
month = "11",
day = "12",
doi = "10.1007/978-1-60761-786-0_13",
language = "English (US)",
volume = "651",
pages = "227--239",
journal = "Methods in molecular biology (Clifton, N.J.)",
issn = "1064-3745",
publisher = "Humana Press",

}

TY - JOUR

T1 - Rescue, amplification, purification, and PEGylation of replication defective first-generation adenoviral vectors.

AU - Barry, Michael A.

AU - Weaver, Eric A.

AU - Hofherr, Sean E.

PY - 2010/11/12

Y1 - 2010/11/12

N2 - Adenoviral gene therapy vectors have been widely studied and used. Their extremely high transduction efficiency and gene delivery in vivo make them attractive for cancer gene therapy approaches. While they are robust, they are also very immunogenic. One approach to mitigate the immunogenicity of adenoviruses and to evade neutralizing antibodies is to coat the virus with the hydrophilic polymer polyethylene glycol (PEG) (1). This chapter details the steps involved when going from recombinant adenoviral vector plasmid all the way to validated PEGylated adenovirus product.

AB - Adenoviral gene therapy vectors have been widely studied and used. Their extremely high transduction efficiency and gene delivery in vivo make them attractive for cancer gene therapy approaches. While they are robust, they are also very immunogenic. One approach to mitigate the immunogenicity of adenoviruses and to evade neutralizing antibodies is to coat the virus with the hydrophilic polymer polyethylene glycol (PEG) (1). This chapter details the steps involved when going from recombinant adenoviral vector plasmid all the way to validated PEGylated adenovirus product.

UR - http://www.scopus.com/inward/record.url?scp=78149237288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149237288&partnerID=8YFLogxK

U2 - 10.1007/978-1-60761-786-0_13

DO - 10.1007/978-1-60761-786-0_13

M3 - Article

C2 - 20686969

AN - SCOPUS:78149237288

VL - 651

SP - 227

EP - 239

JO - Methods in molecular biology (Clifton, N.J.)

JF - Methods in molecular biology (Clifton, N.J.)

SN - 1064-3745

ER -